Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Indian Journal of Hematology and Blood Transfusion
Literature
1.
Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Beau MML et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391–2405CrossRefPubMed
2.
3.
Baxter EJ, Hochhaus A, Bolufer P, Reiter A, Fernandez JM, Senent L et al (2002) The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA. Hum Mol Genet 11(12):1391–1397CrossRefPubMed
4.
Trempat P, Villalva C, Laurent G, Armstrong F, Delsol G, Dastugue N et al (2003) Chronic myeloproliferative disorders with rearrangement of the platelet-derived growth factor alpha receptor: a new clinical target for STI571/Glivec. Oncogene 22(36):5702–5706CrossRefPubMed
5.
Safley AM, Sebastian S, Collins TS, Tirado CA, Stenzel TT, Gong JZ et al (2004) Molecular and cytogenetic characterization of a novel translocation t(4;22) involving the breakpoint cluster region and platelet-derived growth factor receptor-alpha genes in a patient with atypical chronic myeloid leukemia. Genes Chromosomes Cancer 40(1):44–50CrossRefPubMed
6.
Erben P, Gosenca D, Muller MC, Relnhard J, Score J, Valle F et al (2010) Screening for diverse PDGFRA or PDGFRB fusion genes is facilitated by generic quantitative reverse transcriptase polymerase chain reaction analysis. Haematologica 95(5):738–744CrossRefPubMedPubMedCentral
7.
Wang HY, Thorson JA, Broome HE, Rashidi HH, Curtin PC, Dell’Aquila ML (2011) t(4;22)(q12;q11.2) involving presumptive platelet-derived growth factor receptor A and break cluster region in a patient with mixed phenotype acute leukemia. Hum Pathol 42:2029–2036CrossRefPubMed
8.
Yigit N, Wu WW, Subramaniyam S, Mathew S, Geyer JT (2015) BCR–PDGFRA fusion in a T lymphoblastic leukemia/lymphoma. Cancer Genet 208(7):404–407CrossRefPubMed
Metadata
Title
Detection of BCR/PDGRFα Fusion Using Dual Colour Dual Fusion BCR/ABL1 Probe: An Illustrative Report
Authors
Manish Kumar Singh
Arun Sasikumaran Nair Remani
Saurabh Jayant Bhave
Deppak Kumar Mishra
Neeraj Arora
Mayur Parihar
Publication date
01-07-2019
Publisher
Springer India
Published in
Indian Journal of Hematology and Blood Transfusion / Issue 3/2019
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-019-01095-9

Other articles of this Issue 3/2019

Indian Journal of Hematology and Blood Transfusion 3/2019 Go to the issue

Short Communication

Dengue Virus NS1 Exposure Affects von Willebrand Factor Profile and Platelet Adhesion Properties of Cultured Vascular Endothelial Cells

Original Article

Elevated Von Willebrand Factor Antigen Levels are an Independent Risk Factor for Venous Thromboembolism: First Report from North India

Review Article

Allogeneic Hematopoietic Stem Cell Transplantation for Myeloma: Time for an Obituary or Not Just Yet!

Original Article

Utility of Lupus Anticoagulant Assays (APTT-LA, KCT, DPT and DRVVT) in Detection of Antiphospholipid Syndrome (APS) in High Risk Pregnancy Cases

Original Article

Multiparametric Flow Cytometry in Mixed Phenotype Acute Leukemia

Correspondence

Recurrent Arterial and Venous Thrombosis in Chronic Immune Thrombocytopenia: Clinical Paradox and Therapeutic Challenges
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits